Designation Of Romiplostim (Nplate) as an Orphan Drug - Amgen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is designed to regulate the quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and blood products. A notable problem this legislation aims to address is the availability of orphan drugs, which are treatments for rare diseases that often lack sufficient commercial incentive for pharmaceutical companies to develop. The designation of Romiplostim (Nplate) as an orphan drug by the Therapeutic Goods Administration under the authority granted by the Therapeutic Goods Regulations 1990 is an example of how this Act seeks to ensure the availability of vital treatments for rare conditions. Specifically, Romiplostim (Nplate) has been designated for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP), a rare blood disorder. This action by the Delegate of the Secretary, Dr Anthony Gill, on 20 June 2017, highlights the policy objective of facilitating access to necessary medications for rare diseases.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia, facilitates the regulation of therapeutic goods, including medicines, medical devices, and blood products. The Act applies to all therapeutic goods within Australia, encompassing individuals and entities involved in the manufacturing, importing, advertising, supplying, and exporting of these goods. The scope of the Act extends to ensuring the safety, quality, and efficacy of therapeutic goods, with particular emphasis on the protection of public health. In this context, Romiplostim (Nplate) has been designated as an orphan drug for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP). This designation, made under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, recognises Romiplostim's role in addressing rare conditions that affect a small population. The sponsor for Romiplostim, Amgen Australia Pty Ltd, is thereby subject to the specific requirements and benefits associated with orphan drug designation, which may include incentives to encourage the development of treatments for rare diseases. The application of the Therapeutic Goods Act and its Regulations is further extended and refined through subordinate instruments, ensuring comprehensive coverage and effective enforcement of the legislative framework.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as evidenced by the designation of Romiplostim (Nplate) as an orphan drug, involve sections pertaining to the classification and regulation of therapeutic goods, with specific emphasis on orphan drugs (section 16J). This legislation empowers the Delegate of the Secretary to designate certain drugs as orphan drugs, which are intended for the treatment of rare diseases. Romiplostim (Nplate) has been designated for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP), a condition that affects platelet levels in the blood, and this is detailed in the notification signed by Dr Anthony Gill on 20 June 2017. The Act imposes several obligations and requirements on the parties involved, particularly the sponsor of the therapeutic good, Amgen Australia Pty Ltd, in this case. The sponsor must ensure that the product meets the specified criteria for orphan drug designation, including its intended use for a rare disease, and must provide any necessary documentation and information to support the designation. Furthermore, the sponsor must comply with any additional regulatory requirements set forth by the Therapeutic Goods Administration, ensuring that the therapeutic good is safe, of high quality, and effective for its intended use. In terms of potential breaches and their consequences, the Therapeutic Goods Act 1989 includes provisions for offences and penalties. For instance, section 12 of the Act makes it an offence to contravene any provision of the Act or the Regulations, which could result in civil or criminal penalties. Civil penalties include fines up to $222,222 for individuals and $1,111,110 for bodies corporate, depending on the nature and seriousness of the offence. Criminal penalties may include imprisonment for up to five years or both imprisonment and fines, depending on the severity of the breach. These penalties are intended to enforce compliance and protect public health and safety by ensuring that therapeutic goods meet the required standards.